Overview
Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease
Status:
Terminated
Terminated
Trial end date:
2007-04-01
2007-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study was designed to test the hypothesis that the addition of full-dose atorvastatin (80 mg/day) to conventional medical treatment could reduce ischaemic recurrences after non-ST-elevation acute myocardial infarction (NSTE-AMI) in patients with severe and diffuse coronary artery disease (CAD) not amenable to any form of mechanical revascularisation.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
San Filippo Neri General HospitalCollaborator:
Associazione Nazionale Medici Cardiologi OspedalieriTreatments:
Atorvastatin
Atorvastatin Calcium
Criteria
Inclusion Criteria:- non-ST-segment elevation acute myocardial infarction.
- coronary angiography within 48 hours from admission.
- angiographic evidence of severe and diffuse coronary artery disease,not amenable to
conventional direct revascularisation techniques by coronary artery bypass graft
(CABG) or percutaneous coronary intervention (PCI).
Exclusion Criteria:
- ST-segment elevation acute myocardial infarction,
- clinical history of heart failure
- left ventricular ejection fraction <35%,
- any form of severe valvular dysfunction,
- previous implantation or indication to implant a cardioverter-defibrillator during the
index admission,
- any increase in liver enzymes,
- history of any liver or muscle disease,
- renal failure with serum creatinine >2.5 mg/dL (221 mmol/L),
- need for continued use of intravenous medications to relieve anginal symptoms,
- presence of any major comorbidity with life expectancy <24 months.